Application of Nanoformulations in the Treatment of Oral Cancer
Source abstract
Abstract
Abstract Oral cancer, a prevalent malignancy, urgently requires innovative therapies to overcome the side effects and drug resistance of conventional treatments. Nanoformulations, with unique size effects, high drug‐carrying capacities, and targeted delivery advantages, provide a new direction for the precision treatment. This review systematically summarizes the multi‐mechanism applications of nanoformulations in oral cancer treatment: in chemotherapy, nanocarriers based on polymers, lipids and metallic materials improve the bioavailability of drugs by enhancing drug penetration and targeting; photothermal/photodynamic therapy utilizes gold nanoparticles, carbon quantum dots and other agents to achieve local thermal ablation of oral tumors and reactive oxygen species killing; radiotherapy sensitizers improve efficacy by enhancing radiation energy deposition; gene therapy and immunotherapy utilize nanocarriers to deliver nucleic acid drugs or regulate immune microenvironment of oral tumors; combined therapy strategy integrates multiple mechanisms through nano platforms to show synergistic potential. In addition, nanoformulations can be used for the detection, diagnosis, and prevention of oral cancer. Despite the challenges of biocompatibility and large‐scale production, the integration of smart‐responsive nanoformulations with bionic technology shows potential for clinical translation. Future work must optimize the nano‐design through interdisciplinary innovation to promote the development of oral cancer treatment in the direction of high efficiency, low toxicity, individualization, and intelligence.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques · Peptidase Inhibition and Analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
National and Local Joint Engineering Research Center of Biomedical Functional Materials School of Chemistry and Materials Science Nanjing Normal University Nanjing 210023 China
Nanjing Stomatological Hospital Afffliated Hospital of Medical School Nanjing University Nanjing 210008 China
Honors College Nanjing Normal University Nanjing 210023 China
Funding
National Natural Science Foundation of China
References (100+)
Show source-provided references
1. 10.3390/biomedicines1012323110.3390/biomedicines10123231 ↗
2. 10.1038/s41368-023-00249-w10.1038/s41368-023-00249-w ↗
3. 10.3390/cancers1513327010.3390/cancers15133270 ↗
4. 10.1016/S0140-6736(21)01550-610.1016/S0140-6736(21)01550-6 ↗
5. Nogueira T. E. · Medicina Oral Patología Oral y Cirugia Bucal · 2018 · 1
6. 10.3322/caac.2168910.3322/caac.21689 ↗
7. Boogaard W. M. C. · Cancers · 2022 · 14
8. 10.3390/ijms25221240210.3390/ijms252212402 ↗
9. 10.1016/j.apsb.2023.05.01810.1016/j.apsb.2023.05.018 ↗
10. 10.2174/138161282866622090710435410.2174/1381612828666220907104354 ↗
11. Liu X. · Nano Mater. Sci. · 2024 · 47 · 7457
12. 10.1186/1746-160X-9-810.1186/1746-160X-9-8 ↗
13. 10.1089/dna.2009.087410.1089/dna.2009.0874 ↗
14. 10.1016/j.otc.2013.04.00610.1016/j.otc.2013.04.006 ↗
15. 10.1007/s11051-024-06178-x10.1007/s11051-024-06178-x ↗
16. 10.3389/fphar.2020.61610110.3389/fphar.2020.616101 ↗
17. 10.1615/CritRevTherDrugCarrierSyst.202103643710.1615/CritRevTherDrugCarrierSyst.2021036437 ↗
18. 10.33263/BRIAC123.3900393710.33263/BRIAC123.39003937 ↗
19. 10.1016/j.procbio.2022.04.01310.1016/j.procbio.2022.04.013 ↗
20. 10.1002/bit.2845210.1002/bit.28452 ↗
21. 10.1002/hsr2.147110.1002/hsr2.1471 ↗
22. 10.3390/molecules2814539510.3390/molecules28145395 ↗
23. 10.1039/D4RA07193J10.1039/D4RA07193J ↗
24. Liu L. · J. Controlled Release · 2025 · 381
25. 10.1002/adma.20190260410.1002/adma.201902604 ↗
26. 10.1016/j.addr.2013.05.01010.1016/j.addr.2013.05.010 ↗
27. 10.1021/acsabm.3c0072510.1021/acsabm.3c00725 ↗
28. 10.1002/btm2.1000410.1002/btm2.10004 ↗
29. 10.1016/j.ijpharm.2017.05.00410.1016/j.ijpharm.2017.05.004 ↗
30. 10.1016/j.ijbiomac.2022.09.25010.1016/j.ijbiomac.2022.09.250 ↗
31. 10.1080/10717544.2023.225453010.1080/10717544.2023.2254530 ↗
32. 10.1016/j.ijpharm.2024.12431110.1016/j.ijpharm.2024.124311 ↗
33. 10.2147/DDDT.S9965110.2147/DDDT.S99651 ↗
34. 10.1016/j.ijbiomac.2022.10.09010.1016/j.ijbiomac.2022.10.090 ↗
35. 10.1016/j.ijbiomac.2019.03.03110.1016/j.ijbiomac.2019.03.031 ↗
36. Yu L. · Chem. Eng. J. · 2025 · 519
37. 10.1016/j.ijpharm.2023.12314410.1016/j.ijpharm.2023.123144 ↗
38. 10.1007/s12291-024-01239-310.1007/s12291-024-01239-3 ↗
39. 10.1002/adhm.20240305910.1002/adhm.202403059 ↗
40. 10.1186/s12885-021-07849-x10.1186/s12885-021-07849-x ↗
41. 10.1186/s12645-025-00306-510.1186/s12645-025-00306-5 ↗
42. 10.1016/j.ijbiomac.2025.13992610.1016/j.ijbiomac.2025.139926 ↗
43. 10.1016/j.cej.2020.12444610.1016/j.cej.2020.124446 ↗
44. 10.3390/cancers1501026810.3390/cancers15010268 ↗
45. 10.3390/pharmaceutics1511263110.3390/pharmaceutics15112631 ↗
46. 10.1021/acsnano.4c0700010.1021/acsnano.4c07000 ↗
47. 10.1186/s12903-024-04856-910.1186/s12903-024-04856-9 ↗
48. 10.1016/j.jconrel.2011.11.03110.1016/j.jconrel.2011.11.031 ↗
49. 10.1039/D2CS00998F10.1039/D2CS00998F ↗
50. 10.4103/jomfp.JOMFP_29_1710.4103/jomfp.JOMFP_29_17 ↗
51. 10.1016/j.tips.2021.09.00910.1016/j.tips.2021.09.009 ↗
52. 10.1016/j.ijpharm.2017.04.02710.1016/j.ijpharm.2017.04.027 ↗
53. 10.1039/C9TB02818H10.1039/C9TB02818H ↗
54. 10.1016/j.ijbiomac.2024.13897610.1016/j.ijbiomac.2024.138976 ↗
55. 10.1007/s11595-019-2218-410.1007/s11595-019-2218-4 ↗
56. 10.1016/j.matdes.2022.11083810.1016/j.matdes.2022.110838 ↗
57. 10.2147/CMAR.S47779110.2147/CMAR.S477791 ↗
58. 10.1016/j.biopha.2021.11226510.1016/j.biopha.2021.112265 ↗
59. 10.1002/ajmg.c.3203310.1002/ajmg.c.32033 ↗
60. 10.1016/j.taap.2017.07.00810.1016/j.taap.2017.07.008 ↗
61. 10.1016/j.phymed.2020.15338610.1016/j.phymed.2020.153386 ↗
62. 10.1007/s10904-024-03470-010.1007/s10904-024-03470-0 ↗
63. 10.2147/IJN.S45848410.2147/IJN.S458484 ↗
64. 10.2147/IJN.S44287710.2147/IJN.S442877 ↗
65. 10.1186/s12951-024-02433-410.1186/s12951-024-02433-4 ↗
66. 10.1002/adfm.20230023510.1002/adfm.202300235 ↗
67. 10.1016/j.ijbiomac.2023.12452810.1016/j.ijbiomac.2023.124528 ↗
68. 10.1080/15384101.2019.164365810.1080/15384101.2019.1643658 ↗
69. 10.1039/D1TB01310F10.1039/D1TB01310F ↗
70. 10.3390/cancers1503058510.3390/cancers15030585 ↗
71. 10.1016/j.procbio.2024.11.01510.1016/j.procbio.2024.11.015 ↗
72. 10.3390/ijms2609434410.3390/ijms26094344 ↗
73. 10.1016/j.ijpharm.2018.10.06410.1016/j.ijpharm.2018.10.064 ↗
74. 10.1007/s12274-022-4239-010.1007/s12274-022-4239-0 ↗
75. 10.1021/acs.langmuir.9b0300110.1021/acs.langmuir.9b03001 ↗
76. 10.2217/nnm-2019-041510.2217/nnm-2019-0415 ↗
77. 10.34172/jlms.2024.4610.34172/jlms.2024.46 ↗
78. 10.1080/19475411.2020.183959510.1080/19475411.2020.1839595 ↗
79. 10.2147/IJN.S38162810.2147/IJN.S381628 ↗
80. 10.1080/10717544.2021.190917610.1080/10717544.2021.1909176 ↗
81. 10.1186/s12575-024-00252-310.1186/s12575-024-00252-3 ↗
82. 10.1007/s10103-022-03603-210.1007/s10103-022-03603-2 ↗
83. 10.1039/D1TB00719J10.1039/D1TB00719J ↗
84. 10.1111/cpr.1278610.1111/cpr.12786 ↗
85. 10.1016/j.colsurfa.2024.13440910.1016/j.colsurfa.2024.134409 ↗
86. 10.1039/D3NR02088F10.1039/D3NR02088F ↗
87. 10.1016/j.jconrel.2023.12.05610.1016/j.jconrel.2023.12.056 ↗
88. 10.1039/D1BM01780B10.1039/D1BM01780B ↗
89. 10.1016/j.ijpharm.2025.12522410.1016/j.ijpharm.2025.125224 ↗
90. 10.2147/IJN.S43491710.2147/IJN.S434917 ↗
91. 10.1016/j.ejmech.2024.11650810.1016/j.ejmech.2024.116508 ↗
92. 10.1016/j.biomaterials.2013.11.06610.1016/j.biomaterials.2013.11.066 ↗
93. 10.3390/pharmaceutics1602022410.3390/pharmaceutics16020224 ↗
94. 10.1016/j.ccr.2024.21610110.1016/j.ccr.2024.216101 ↗
95. 10.1021/acs.langmuir.0c0231610.1021/acs.langmuir.0c02316 ↗
96. 10.2147/IJN.S32976210.2147/IJN.S329762 ↗
97. 10.1016/j.radphyschem.2022.10999010.1016/j.radphyschem.2022.109990 ↗
98. Sharma G. · Technol. Cancer Res. Treatment · 2023 · 2210.1177/15330338231189593 ↗
99. 10.1021/acsomega.2c0671410.1021/acsomega.2c06714 ↗
100. 10.1002/advs.20230956910.1002/advs.202309569 ↗